Results 131 to 140 of about 591,252 (334)

Abstracts of the joint meeting of the Clinical Genetics Society and the Clinical Molecular Genetics Society held on 19 and 20 April 1990 at University of Newcastle upon Tyne Medical School [PDF]

, 1990
Mary Porteous, John Burn, S Proctort, C. Geoffrey Woods, Sarah Bundey, A. Malcolm R. Taylor   +5 more
openalex   +1 more source

ABC of Clinical Genetics. Clinical genetic services. [PDF]

BMJ, 1989
openaire   +3 more sources

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

Molecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy, Heather Fairfield, Victoria E. DeMambro, Samaa Fadel, Carlos A. Gartner, Michelle Karam, Christian Potts, Princess Rodriguez, Ya‐Wei Qiang, Habib Hamidi, Xiangnan Guan, Calvin P. H. Vary, Michaela R. Reagan   +12 more
wiley   +1 more source

Underrepresentation of the term cerebral palsy in clinical genetics databases. [PDF]

Am J Med Genet A, 2022
Srivastava S, Lewis SA, Kruer MC, Poduri A.   +3 more
europepmc   +1 more source

Molecular genetics of Alport syndrome: the clinical consequences [PDF]

, 1993
Bertrand Knebelmann, Corinne Antignac, Marie‐Claire Gubler, Jean‐Pierre Grünfeld   +3 more
openalex   +1 more source

TRPM4 contributes to cell death in prostate cancer tumor spheroids, and to extravasation and metastasis in a zebrafish xenograft model system

Molecular Oncology, EarlyView.
Transient receptor potential melastatin‐4 (TRPM4) is overexpressed in prostate cancer (PCa). Knockout of TRPM4 resulted in reduced PCa tumor spheroid size and decreased PCa tumor spheroid outgrowth. In addition, lack of TRPM4 increased cell death in PCa tumor spheroids.
Florian Bochen, Saurav Subedi, Federico La Manna, Sofia Jarrin, Irida Papapostolou, Marianna Kruithof‐de Julio, Christine Peinelt   +6 more
wiley   +1 more source

Genetics-Driven Personalized Disease Progression Model [PDF]

arXiv
Modeling disease progression through multiple stages is critical for clinical decision-making for chronic diseases, e.g., cancer, diabetes, chronic kidney diseases, and so on. Existing approaches often model the disease progression as a uniform trajectory pattern at the population level. However, chronic diseases are highly heterogeneous and often have
arxiv  

Medical genetics: advances in brief: The fish odour syndrome: biochemical, familial, and clinical aspects [PDF]

, 1994
A M Norman
openalex   +1 more source

Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer

Molecular Oncology, EarlyView.
Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti, Shingo Inagaki, Tuyen Thuy Bich Ho, Akihiro Seki, Keiko Yoshida, Kosuke Satomura, Yoshio Sakai, Shuichi Kaneko, Taro Yamashita   +8 more
wiley   +1 more source

Clinical genetics: past, present and future. [PDF]

Eur J Hum Genet, 2022
Tromans E, Barwell J.
europepmc   +1 more source